Zacks Small Cap Has Strong Forecast for RANI FY2025 Earnings

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) – Analysts at Zacks Small Cap upped their FY2025 earnings per share estimates for Rani Therapeutics in a report released on Monday, October 20th. Zacks Small Cap analyst J. Vandermosten now expects that the company will earn ($0.34) per share for the year, up from their prior forecast of ($0.49). The consensus estimate for Rani Therapeutics’ current full-year earnings is ($1.01) per share. Zacks Small Cap also issued estimates for Rani Therapeutics’ Q4 2025 earnings at ($0.01) EPS, FY2026 earnings at ($0.20) EPS and FY2027 earnings at ($0.17) EPS.

Rani Therapeutics (NASDAQ:RANI) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01.

Other equities research analysts have also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and set a $11.00 price objective on shares of Rani Therapeutics in a research report on Tuesday. Maxim Group lifted their price objective on Rani Therapeutics from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Monday. Wall Street Zen raised Rani Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Rani Therapeutics in a research note on Wednesday, October 8th. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.50.

Rani Therapeutics Stock Performance

Rani Therapeutics stock opened at $2.41 on Wednesday. The firm has a market cap of $173.21 million, a price-to-earnings ratio of -2.65 and a beta of -0.02. Rani Therapeutics has a 52-week low of $0.39 and a 52-week high of $3.87. The firm has a 50 day moving average price of $0.65 and a two-hundred day moving average price of $0.69.

Insider Buying and Selling

In other Rani Therapeutics news, major shareholder South Cone Investments Limited sold 4,000,000 shares of the stock in a transaction on Tuesday, October 21st. The stock was sold at an average price of $2.77, for a total transaction of $11,080,000.00. Following the sale, the insider owned 2,379,194 shares in the company, valued at approximately $6,590,367.38. This represents a 62.70% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 45.08% of the company’s stock.

Hedge Funds Weigh In On Rani Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Well Done LLC acquired a new stake in shares of Rani Therapeutics in the 2nd quarter valued at about $27,000. Janney Montgomery Scott LLC raised its position in shares of Rani Therapeutics by 102.9% in the 2nd quarter. Janney Montgomery Scott LLC now owns 55,200 shares of the company’s stock worth $28,000 after buying an additional 28,000 shares during the period. King Luther Capital Management Corp grew its position in Rani Therapeutics by 75.8% during the first quarter. King Luther Capital Management Corp now owns 58,000 shares of the company’s stock valued at $73,000 after acquiring an additional 25,000 shares during the period. CWA Asset Management Group LLC increased its stake in Rani Therapeutics by 80.0% during the third quarter. CWA Asset Management Group LLC now owns 150,000 shares of the company’s stock worth $75,000 after acquiring an additional 66,667 shares during the last quarter. Finally, Kestra Private Wealth Services LLC raised its holdings in shares of Rani Therapeutics by 16.3% in the 1st quarter. Kestra Private Wealth Services LLC now owns 139,156 shares of the company’s stock worth $175,000 after purchasing an additional 19,536 shares during the period. 30.19% of the stock is currently owned by institutional investors and hedge funds.

About Rani Therapeutics

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies.